(IN BRIEF) AstraZeneca's supplemental New Drug Application (sNDA) for Tagrisso (osimertinib) in combination with chemotherapy has been granted Priority Review…
(IN BRIEF) GSK has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the…
(IN BRIEF) EpimAb Biotherapeutics, a clinical-stage biopharmaceutical company specializing in multispecific antibodies, and Almirall, a global biopharmaceutical company focused on…
(IN BRIEF) QIAGEN is organizing the Global TB Clinical and Educational Summit 2023, running from October 17-19, with the theme…
(IN BRIEF) AstraZeneca has revealed the eight winners of its 2023 R&D Postdoctoral Challenge, an initiative that supports early-career scientists…
(IN BRIEF) AstraZeneca is set to present new data at the 12th annual IDWeek conference, emphasizing the role of long-acting…
(IN BRIEF) Alexion, a subsidiary of AstraZeneca Rare Disease, is set to present new data at the 9th Joint Meeting…
(IN BRIEF) AstraZeneca has unveiled data from four pivotal Phase III trials at the European Society for Medical Oncology (ESMO)…
(IN BRIEF) Roche has announced positive late-breaking data from the Phase III OCARINA II study, which demonstrates the effectiveness of…
(IN BRIEF) Merck has presented new data on evobrutinib, an investigational BTK inhibitor, at the 9th Joint ECTRIMS-ACTRIMS congress. The…